<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Between February 1998 and October 2007, 97 (69 male, 28 female) patients with acquired <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> and a median age of 18 years (range, 2-39) received related allogeneic hematopoietic stem cell transplantation </plain></SENT>
<SENT sid="1" pm="."><plain>Ninety-five patients received bone marrow grafts and two patients G-CSF primed peripheral blood stem cell transplantation </plain></SENT>
<SENT sid="2" pm="."><plain>The donors were genotypically HLA-identical siblings in 94 cases, HLA-matched parents in 2 cases and a syngeneic twin in 1 case </plain></SENT>
<SENT sid="3" pm="."><plain>Median time from diagnosis to transplantation was 2 months (range, 1-15) </plain></SENT>
<SENT sid="4" pm="."><plain>Conditioning regimen consisted of <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> combined with antithymocyte globulin in <z:hpo ids='HP_0000001'>all</z:hpo> patients </plain></SENT>
<SENT sid="5" pm="."><plain>For <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft versus host disease</z:e> (GVHD) prophylaxis, <z:hpo ids='HP_0000001'>all</z:hpo> patients received <z:chebi fb="0" ids="44185">methotrexate</z:chebi> and <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>Eighty-six patients showed evidence of hematopoietic engraftment </plain></SENT>
<SENT sid="7" pm="."><plain>Eight patients died before engraftment </plain></SENT>
<SENT sid="8" pm="."><plain>Rejection rate was 14.8% with three primary graft failures and eight secondary graft rejections occurring between 2 and 27 months post transplantation </plain></SENT>
<SENT sid="9" pm="."><plain>Of the 11 rejecting patients, 3 died from <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> and 8 proceeded to a second transplantation </plain></SENT>
<SENT sid="10" pm="."><plain>Among the eight patients re-transplanted, seven are alive with successful second engraftments and one died from <z:hpo ids='HP_0011009'>acute</z:hpo> grade III GVHD </plain></SENT>
<SENT sid="11" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> GVHD occurred in 15.5% and extensive <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD in only 5.3% of patients </plain></SENT>
<SENT sid="12" pm="."><plain>The 4-year overall probability of survival was 76.8% </plain></SENT>
<SENT sid="13" pm="."><plain><z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">Infection</z:e> was the cause of 81.1% of <z:hpo ids='HP_0011420'>deaths</z:hpo> </plain></SENT>
<SENT sid="14" pm="."><plain>The major factor affecting survival was <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> before transplantation </plain></SENT>
<SENT sid="15" pm="."><plain>Major ABO donor-recipient incompatibility, disease severity and <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD had also negative impact on survival </plain></SENT>
<SENT sid="16" pm="."><plain>These results could be improved by reducing the time to transplant and by a more efficient supportive care policy.Bone Marrow Transplantation advance online publication, 27 July 2009; doi:10.1038/bmt.2009.175 </plain></SENT>
</text></document>